FIGS, Inc. (FIGS) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

73OpportunityDD: Jul 17, 2026Analyst: 72

paidPrice at analysis date

USD 10.4 (17/07/2026)

domainMkt cap

$1.74B

pie_chartShares

167.05M

candlestick_chart52W

$5.66-$17.48

trending_downShort interest

4.7%

INFONYSEApparel Manufacturing388 employeesFounded 2013

Verdict: Favorable Risk/Reward —

Post-guidance-cut fallen angel with genuine inflection: Q4 2025 revenue +33%, Q1 2026 +28%, FY26 guidance raised twice. ~$300M net cash ($1.80/sh) provides a hard floor at ~2.6x market cap of the cash cushion. Stock already recovered +84% from $5.66 low but still ~40% below 52W high with Q2 earnings (Aug 6, 2026) as near-term catalyst. Asymmetric setup validated: bull +70% / bear −24%, ratio ~2.9x.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-17

FIGS, Inc. (FIGS)

Apparel Manufacturing · NYSE · Santa Monica

"Reaccelerating DTC brand with net-cash cushion — modest upside after 84% recovery."

Net cash $300M FY26 guidance raised Q1 rev +28% YoY Insider Rule 10b5-1 sales Tariff exposure China

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/Sales forward × Peer Median + Net Cash Add-back

Fair value base case

USD 12.6

Range: USD 8.00-USD 17.5

Price at analysis date: USD 10.4 (17/07/2026)

Base upside/downside: +21%

EV/Sales forward multiple derived from peer median (LULU 1.5x, CROX 1.8x, YETI 1.4x, ONON 4.0x → median 1.65x, +25% growth premium = ~2.0-2.5x). FY26E revenue $720M mid-point of raised guidance ($700-733M implied by +14-16%). Implicit multiple 18.6x EV/EBITDA within tolerance vs nominal 15x. Sensitivity ±0.5x EV/Sales fw moves FV ~17%. Analyst consensus median $17.63 sits between base and bull; my base case is 29% below because I discount for tariff drag ($40M reserve) and RSU dilution (~1.5%/yr) that consensus tends to omit. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core business EV	$720M FY26E rev × 2.5x EV/Sales fw (peer median 2.0x + 25% growth premium) = $1,800M / 167M sh	+10.78
Net cash floor	$300M cash+ST investments − $0 LT debt (Q1 26 pro-forma FCF) / 167M sh	+1.80
Buyback authorization value	$55M residual authorization (of $100M) × 60% likely execution / 167M sh	+0.20
Tariff/inventory reserve	−$40M reserve (China tariff pass-through drag) / 167M sh	−0.24
RSU dilution 12M	~1.5% net dilution × $10.41 ≈ $0.16 haircut (executive RSU vesting, Rule 10b5-1 sales)	−0.16
FV base case	Arithmetic sum: 10.78 + 1.80 + 0.20 − 0.24 − 0.16	≈ $12.38

Bull

$17–$19

Probability: 25%

FY26 revenue tops $750M (+19% vs +14-16% guide), Adj EBITDA margin >13.5%, international +40% YoY sustained. Multiple re-rates to 3.5x EV/Sales fw. Strategic acquirer interest emerges (LVMH, Bella+Canvas type).

Base

$11–$13

Probability: 50%

Guidance delivered (+14-16% rev, 13% EBITDA margin), Q2 in-line, tariff mitigation on-track. Multiple stabilizes at 2.5x fw sales. Buyback executes 60% of authorization. FV $12.60 median.

Bear

$7–$9

Probability: 25%

Q2 revenue misses guide, tariff pass-through hits gross margin >200bps, international deceleration. Multiple compresses to 1.5x fw sales. Floor from $1.80/sh net cash + $700M rev × 1.5x = $8/sh. Downside limited by cash.

Methodology: EV/Sales forward multiple derived from peer median (LULU 1.5x, CROX 1.8x, YETI 1.4x, ONON 4.0x → median 1.65x, +25% growth premium = ~2.0-2.5x). FY26E revenue $720M mid-point of raised guidance ($700-733M implied by +14-16%). Implicit multiple 18.6x EV/EBITDA within tolerance vs nominal 15x. Sensitivity ±0.5x EV/Sales fw moves FV ~17%. Analyst consensus median $17.63 sits between base and bull; my base case is 29% below because I discount for tariff drag ($40M reserve) and RSU dilution (~1.5%/yr) that consensus tends to omit. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Q1 2026 confirmed inflection — full-year guidance raised

FIGS raised FY26 net revenue guidance to +14-16% growth (from +10-12%) and Adj EBITDA margin to 13.0-13.2% (from 12.7-12.9%) after Q1 revenue rose +28% YoY to $159.9M with active customers topping 3M. International revenue +50% YoY. Analyst upgrades cascade: KeyBanc $19, Roth $18, BTIG $20, Morgan Stanley $15, Oppenheimer $22. The narrative has flipped from "structural decline" to "sustained recovery".

⚠️ Methodology note: Screening in ASYMMETRIC mode identified FIGS as a [FALLEN_ANGEL / INFLECTION] hybrid: −67% from Feb 2026 low following guidance disappointment, then +84% recovery on Q4/Q1 reacceleration. Fair value derived bottom-up from apparel/DTC peer EV/Sales median with premium for growth reacceleration, then cross-checked against sum-of-parts (business + net cash). Verdict is independent of screening classification.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟢 Short Interest

~4.7%

~7.9M shares short of 167M outstanding, ~5 days to cover. Interpretation: low — reflects contained bearish positioning post-Q1 beat.

🟢 Share dilution (1Y)

−1.2%

From ~169M to ~167M shares via buyback offsetting RSU vesting. $100M buyback authorization; ~$45M executed FY24. Net reduction ongoing.

🟢 Buyback

$100M auth

Program increased +$50M in 2025; ~$55M residual capacity. Priority: opportunistic execution at compressed multiples. Active during weakness.

Short Interest — context

FIGS — 4.7%

4.7%

Short interest at 4.7% is low for a stock that recently had a −67% drawdown; suggests bears have already covered post-Q1 beat. Insider activity: Executive Chair Heather Hasson sold 556K shares open-market on 2026-03-03 after option exercise (~$8M at then price ~$14); CEO Catherine Spear sold 62K shares 2026-02 for RSU tax cover under Rule 10b5-1. Not a red flag — pre-arranged programmatic sales, but material $$$ crossing $500K threshold.

$Financial analysis — FY2025 & Q1 2026

Revenue TTM

$666M

+18.7% YoY (accelerating)

Gross margin

66.5%

−100bps YoY (tariff drag)

Cash + ST inv.

$277M

+10% YoY, zero LT debt

Adj EBITDA margin

13.1%

Guidance raised (was 12.7%)

Item	FY2023	FY2024	FY2025	Q1 2026	Guidance FY2026
Revenue ($M)	545	556	631	160	~720 (+14-16%)
Gross margin %	67.6%	67.5%	66.7%	65.7%	65-66% (tariff)
Adj EBITDA ($M)	81	72	83	21	~95 (13-13.2%)
Net income ($M)	21	3	34	5	~35-40E
FCF ($M)	50	36	55	—	~50E

Sources: FIGS 10-K FY25, 10-Q Q1 26, earnings releases. Guidance updated post-Q1 26 call (May 7, 2026).

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	125.0	142.5	151.2	212.4	159.9
Growth YoY %	+2%	+3%	+7%	+33%	+28%
Gross margin %	67.0	67.1	66.5	66.2	65.7
Adj EBITDA ($M)	14.5	15.8	17.2	35.5	21.0
End-of-period cash ($M)	252	261	273	282	277

Financial position and sustainability

Runway (net cash / OpEx)

>10 years

Adj EBITDA margin trend

13.1% (up)

DTC mix (% of revenue)

~90%

International revenue growth

+50% YoY (Q1 26)

account_tree

Business model — Premium healthcare DTC apparel

Direct-to-consumer scrubs pioneer with brand pricing power

FIGS designs, markets, and sells premium healthcare apparel (scrubs, underscrubs, outerwear, lifestyle) primarily direct-to-consumer via wearfigs.com. ~90% DTC mix (highest in publicly traded apparel), 3M+ active customers, 66% gross margin (2x industry average). Fabrics use proprietary "FIONx" antimicrobial technology. Growth flywheel: viral healthcare-worker influencer marketing → scrub category dominance → adjacency expansion (footwear, loungewear, lab coats) → international rollout (UK, EU, Canada launched 2024-25). Q4 2025 revenue inflection (+33%) confirmed sustained recovery narrative previously in doubt.

gavel

Legal, regulatory and risk analysis

China tariff exposure

Moderate

~40-50% of production China-sourced. Management targeting reduction to 25-30% by FYE. 100-200bps GM drag expected in H2 2026 before mitigation. Direct pass-through to consumer TBD.

Insider selling activity

Moderate

Executive Chair Hasson sold 556K shares open-market 2026-03-03 (~$8M, post-option exercise). CEO Spear 62K RSU tax cover. Both Rule 10b5-1 pre-arranged — not signal, but material size.

Consumer discretionary macro

Moderate

Healthcare workers are a defensive customer segment (recurring uniform replacement), but premium price points ($40+ per top) exposed to trade-down risk. LULU/CROX have flagged bifurcated consumer.

Competition scaling up

Moderate

Amazon Essentials, Costco, Wonderwink and Ceil private label attacking mid-tier. Bella+Canvas Healthcare launched 2025. FIGS defends via brand equity + product innovation cadence, but pricing headwind possible.

Fortress balance sheet

Positive

$277M cash + ST investments, zero LT debt, current ratio 4.9, D/E 0.14. 16% of market cap in net cash; runway effectively infinite. Enables buyback, international expansion, M&A optionality.

Growth reacceleration

Positive

Q4 25 rev +33%, Q1 26 +28%, guidance raised twice. International +50% YoY (Q1). Active customers surpass 3M for first time. Analyst upgrades cascade Feb-Jun 2026.

Class-action / SEC

Positive

No pending securities class-action, SEC investigation, or short-seller report identified in the last 12 months. Clean governance profile.

Corporate governance dual class

Moderate

Dual-class share structure: Class B (super-voting) held by co-founders Hasson & Spear. Limits activist pressure; strategic sale (if desired by founders) could unlock value but shareholders have little say.

article

SWOT analysis

Strengths

+Category-defining brand in healthcare apparel (recurring purchase, sticky customers)
+Fortress balance sheet: $277M net cash, zero LT debt, 16% of market cap
+66.5% gross margin — 2x industry average, DTC-heavy mix (~90%)
+Growth reacceleration confirmed: Q4 25 +33%, Q1 26 +28% YoY
+International runway (+50% YoY off small base) with UK/EU/Canada opening

Weaknesses

−Concentration in China production (~40-50%) exposed to tariff swings
−Dual-class founder control limits shareholder governance leverage
−Gross margin compression (66.5% down from 67.6%) despite reacceleration
−Insider open-market selling by Executive Chair ($8M in March 2026)

Opportunities

→Non-scrub adjacencies (loungewear, footwear, lab coats) — ~25% of rev, growing fast
→B2B channel to hospitals/systems (uniform contracts) — nascent, high-value
→Strategic acquirer interest at recovered multiple (LVMH, Under Armour, Levi type)
→$55M residual buyback authorization deployable during weakness

Threats

!Amazon/Costco/private-label scrub attack on price-sensitive segment
!Prolonged tariff escalation squeezing GM below guided 65%
!Consumer discretionary slowdown, healthcare labor cost pressures
!Multiple compression if growth decelerates to single digits again

article

Summary by assessment area

🟢 Financial risk — Low

Net cash floor $1.80/sh anchors downside
Zero LT debt, current ratio 4.9
FCF positive, 10%+ EBITDA margin

🟡 Business risk — Moderate

Q4/Q1 inflection real but must sustain
Tariff-driven GM drag near-term
Competitive pressure mid-tier scrubs

🔵 Valuation risk — Moderate

Post-recovery: +84% off April lows
Base FV +21% vs analyst target +76%
Bull/bear asymmetry ~2.9x favorable

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "FIGS ha completato l'inflection: Q4 25 revenue +33%, Q1 26 +28%, guidance FY26 alzata due volte. Net cash $277M copre il 16% della market cap. Post-recovery +84% dai minimi, upside residuo +20-25% con Q2 earnings 6 agosto come catalizzatore binario.", "en": "FIGS has completed the inflection: Q4 25 revenue +33%, Q1 26 +28%, FY26 guidance raised twice. Net cash $277M covers 16% of market cap. Post-recovery +84% from lows, remaining upside +20-25% with Q2 earnings August 6 as binary catalyst."}, "bull_points": [ {"it": "Fortress balance sheet: $277M cassa + investimenti, zero debito, ~16% market cap in cash", "en": "Fortress balance sheet: $277M cash + investments, zero debt, ~16% market cap in cash"}, {"it": "Q4 25 e Q1 26 confermano inflection: revenue +33% e +28% YoY con guidance FY26 alzata due volte", "en": "Q4 25 and Q1 26 confirm inflection: revenue +33% and +28% YoY with FY26 guidance raised twice"}, {"it": "International +50% YoY (Q1 26) con UK/EU/Canada in scaling — runway pluriennale", "en": "International +50% YoY (Q1 26) with UK/EU/Canada scaling — multi-year runway"} ], "bear_points": [ {"it": "Post-recovery +84% dai minimi limita upside residuo: base FV +21% vs target consensus +76%", "en": "Post +84% recovery from lows caps residual upside: base FV +21% vs consensus target +76%"}, {"it": "GM compression 66.5% (da 67.6%) per esposizione tariffe Cina ~40-50% produzione", "en": "GM compression to 66.5% (from 67.6%) due to ~40-50% China production tariff exposure"}, {"it": "Insider selling: Executive Chair Hasson vendite open-market $8M in marzo 2026", "en": "Insider selling: Executive Chair Hasson open-market sales of $8M in March 2026"} ], "risks": [ {"it": "Dual-class founder control limita governance esterna", "en": "Dual-class founder control limits external governance"}, {"it": "Attacco Amazon/Costco/private-label sul mid-tier scrubs", "en": "Amazon/Costco/private-label attack on mid-tier scrubs"}, {"it": "Slowdown consumer discretionary + tariffe cinesi prolungate", "en": "Consumer discretionary slowdown + prolonged China tariffs"} ] }

Sources & Disclaimer

Sources: FIGS 10-K FY25, 10-Q Q1 2026, earnings releases (May 7, 2026 & Feb 23, 2026), Yahoo Finance, StockAnalysis.com, Simply Wall St, Fintel, MarketBeat, Motley Fool Q1 26 earnings transcript, TheFly analyst updates (KeyBanc, Roth, BTIG, Morgan Stanley, Oppenheimer), Investing.com. Market data — last verified close 2026-07-16: FIGS ~$10.41, market cap ~$1.74B, 52W: $5.66–$17.48, 167.05M shares outstanding. Short interest: ~4.7%. Analyst price target consensus $17.63 (median, 9 analysts, updated Jul 2026). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.